Literature DB >> 26282324

Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.

Qian Ma1, Jianmin Yang2, Thomas Li2, Teresa A Milner3, Barbara L Hempstead4.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder characterized by massive loss of medium spiny neurons in the striatum. However, the mechanisms by which mutant huntingtin leads to this selective neuronal death remain incompletely understood. Brain-derived neurotrophic factor (BDNF) has been shown to be neuroprotective on HD striatal neurons both in vitro and in vivo. ProBDNF, the precursor of mature BDNF (mBDNF), also can be secreted but promotes apoptosis of neurons expressing p75(NTR) and sortilin receptors. Although a reduction of total striatal BDNF protein has been reported in HD patients and mouse models, it remains unclear whether conversion of proBDNF to mBDNF is altered in HD, and whether the proBDNF receptors, p75(NTR) and sortilin are dysregulated, leading to impaired striatal neuron survival. To test these hypotheses, we generated bdnf-HA knock-in (KI) mice on the zQ175 HD background to accurately quantitate the levels of both proBDNF and mBDNF in the HD striatum. In aged zQ175 HD mice, we observed a significant loss of mBDNF and decreased TrkB activation, but no increase of proBDNF or p75(NTR) levels either in the sensorimotor cortex or the striatum. However, immunoreactivities of p75(NTR) and sortilin receptor are both increased in immature striatal oligodendrocytes, which associate with significant myelin defects in the HD striatum. Taken together, the present study indicates that diminished mature BDNF trophic signaling through the TrkB receptor, rather than an induction in proBDNF, is a main contributing factor to the vulnerability of striatal neurons in the zQ175 HD mouse model.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortex; Huntington's disease; Mature BDNF; Myelin; Oligodendrocyte; ProBDNF; Sortilin; Striatum; p75(NTR); zQ175 mice

Mesh:

Substances:

Year:  2015        PMID: 26282324      PMCID: PMC4819334          DOI: 10.1016/j.nbd.2015.08.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  60 in total

1.  ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury.

Authors:  Michael S Beattie; Anthony W Harrington; Ramee Lee; Ju Young Kim; Sheri L Boyce; Frank M Longo; Jacqueline C Bresnahan; Barbara L Hempstead; Sung Ok Yoon
Journal:  Neuron       Date:  2002-10-24       Impact factor: 17.173

2.  Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery.

Authors:  Chiara Zuccato; Daniel Liber; Catarina Ramos; Alessia Tarditi; Dorotea Rigamonti; Marzia Tartari; Marta Valenza; Elena Cattaneo
Journal:  Pharmacol Res       Date:  2005-08       Impact factor: 7.658

3.  Brain-derived neurotrophic factor in Huntington disease.

Authors:  I Ferrer; E Goutan; C Marín; M J Rey; T Ribalta
Journal:  Brain Res       Date:  2000-06-02       Impact factor: 3.252

4.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

5.  P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp.

Authors:  Kevin C Wang; Jieun A Kim; Rajeev Sivasankaran; Rosalind Segal; Zhigang He
Journal:  Nature       Date:  2002-10-20       Impact factor: 49.962

6.  NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions.

Authors:  A Chang; A Nishiyama; J Peterson; J Prineas; B D Trapp
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

7.  LINGO-1 negatively regulates myelination by oligodendrocytes.

Authors:  Sha Mi; Robert H Miller; Xinhua Lee; Martin L Scott; Svetlane Shulag-Morskaya; Zhaohui Shao; Jufang Chang; Greg Thill; Melissa Levesque; Mingdi Zhang; Cathy Hession; Dinah Sah; Bruce Trapp; Zhigang He; Vincent Jung; John M McCoy; R Blake Pepinsky
Journal:  Nat Neurosci       Date:  2005-05-15       Impact factor: 24.884

8.  Activation of p75NTR by proBDNF facilitates hippocampal long-term depression.

Authors:  Newton H Woo; Henry K Teng; Chia-Jen Siao; Cristina Chiaruttini; Petti T Pang; Teresa A Milner; Barbara L Hempstead; Bai Lu
Journal:  Nat Neurosci       Date:  2005-07-17       Impact factor: 24.884

9.  Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer.

Authors:  A P Bemelmans; P Horellou; L Pradier; I Brunet; P Colin; J Mallet
Journal:  Hum Gene Ther       Date:  1999-12-10       Impact factor: 5.695

10.  Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.

Authors:  C Zuccato; A Ciammola; D Rigamonti; B R Leavitt; D Goffredo; L Conti; M E MacDonald; R M Friedlander; V Silani; M R Hayden; T Timmusk; S Sipione; E Cattaneo
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

View more
  15 in total

1.  Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice.

Authors:  Nuria Suelves; Andrés Miguez; Saray López-Benito; Gerardo García-Díaz Barriga; Albert Giralt; Elena Alvarez-Periel; Juan Carlos Arévalo; Jordi Alberch; Silvia Ginés; Verónica Brito
Journal:  Mol Neurobiol       Date:  2018-05-27       Impact factor: 5.590

2.  The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.

Authors:  A B Wehner; A M Milen; R L Albin; B A Pierchala
Journal:  Neuroscience       Date:  2016-03-03       Impact factor: 3.590

3.  Differential regulation of Kidins220 isoforms in Huntington's disease.

Authors:  Álvaro Sebastián-Serrano; Ana Simón-García; Alicia Belmonte-Alfaro; Julia Pose-Utrilla; María Santos-Galindo; Ana Del Puerto; Lucía García-Guerra; Ivó H Hernández; Giampietro Schiavo; Miguel R Campanero; José J Lucas; Teresa Iglesias
Journal:  Brain Pathol       Date:  2019-07-16       Impact factor: 7.611

4.  Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease.

Authors:  Khanh Q Nguyen; Vladimir V Rymar; Abbas F Sadikot
Journal:  Front Cell Neurosci       Date:  2016-03-09       Impact factor: 5.505

Review 5.  Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.

Authors:  Danielle A Simmons
Journal:  J Huntingtons Dis       Date:  2017

6.  Low pH-induced conformational change and dimerization of sortilin triggers endocytosed ligand release.

Authors:  Nadia Leloup; Philip Lössl; Dimphna H Meijer; Martha Brennich; Albert J R Heck; Dominique M E Thies-Weesie; Bert J C Janssen
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

7.  A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.

Authors:  Danielle A Simmons; Nadia P Belichenko; Ellen C Ford; Sarah Semaan; Marie Monbureau; Sruti Aiyaswamy; Cameron M Holman; Christina Condon; Mehrdad Shamloo; Stephen M Massa; Frank M Longo
Journal:  Hum Mol Genet       Date:  2016-11-15       Impact factor: 6.150

Review 8.  Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases.

Authors:  Tadahiro Numakawa; Haruki Odaka; Naoki Adachi
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

9.  Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.

Authors:  Ana Sanchis; María Adelaida García-Gimeno; Antonio José Cañada-Martínez; María Dolores Sequedo; José María Millán; Pascual Sanz; Rafael P Vázquez-Manrique
Journal:  Exp Mol Med       Date:  2019-06-05       Impact factor: 8.718

10.  TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.

Authors:  Danielle A Simmons; Michelle L James; Nadia P Belichenko; Sarah Semaan; Christina Condon; Jason Kuan; Adam J Shuhendler; Zheng Miao; Frederick T Chin; Frank M Longo
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.